Multiple myeloma patients undergoing a stem cell transplant in an outpatient setting spent about a week less in the hospital than those undergoing the…
News
The U.S. Food and Drug Administration (FDA) has placed a hold on clinical testing of CART-ddBCMA, a cell therapy that Arcellx and Kite…
The U.S. Food and Drug Administration (FDA) has cleared the launch of a Phase 1b trial to test STAR-LLD, Starton Therapeutics’ experimental continuous delivery…
Janssen is asking the U.S. Food and Drug Administration (FDA) to expand approval its cell therapy Carvykti (ciltacabtagene autoleucel) to allow for earlier…
Carvykti (ciltacabtagene autoleucel) significantly reduces the risk of disease progression or death in adults with multiple myeloma who received one to three prior lines…
A gene therapy designed by Kelonia Therapeutics to work as an off-the-shelf or readily available CAR T-cell therapy for multiple myeloma showed early…
Sarclisa (isatuximab), given on top of standard treatment with Kyprolis (carfilzomib) and the steroid dexamethasone, was found to delay disease progression by almost…
Survival outcomes for people with multiple myeloma have improved substantially over the last two decades, likely due to the availability of new, more effective…
Most patients with hard-to-treat multiple myeloma given NXC-201 — Nexcella’s experimental point-of-care CAR T-cell therapy — as part of a clinical trial in…
The U.S. Food and Drug Administration (FDA) has agreed to review an application that, if approved, would allow the cell therapy Abecma (idecabtagene…
